Nifty
:
19674.25
Sensex
:
66009.15
-68.10 (-0.34%)
-221.09 (-0.33%)
Nifty
Sensex
:
:
19674.25
66009.15
-68.10 (-0.34%)
-221.09 (-0.33%)

Biocon Ltd.

Pharmaceuticals & Drugs - Global

Rating :
48/99

BSE: 532523 | NSE: BIOCON

NSE BSE
267.00
21-Sep-2023
  • Open
  • High
  • Low
  • Previous Close
  •  275.00
  •  276.00
  •  266.20
  •  273.20
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  4855030
  •  13111.29
  •  299.15
  •  191.55

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 32,062.02
  • 76.39
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 47,432.62
  • 0.56%
  • 1.80

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.64%
  • 0.91%
  • 13.34%
  • FII
  • DII
  • Others
  • 9.52%
  • 12.56%
  • 3.03%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.53
  • 15.17
  • 16.09

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.92
  • 13.53
  • 10.23

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 1.12
  • -12.54
  • -17.36

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 54.05
  • 61.86
  • 65.34

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.05
  • 5.27
  • 4.86

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.45
  • 22.50
  • 21.20

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Dec 22
Dec 21
Var%
Sep 22
Sep 21
Var%
Net Sales
3,422.60
2,139.50
59.97%
3,773.90
2,408.80
56.67%
2,941.10
2,174.20
35.27%
2,319.70
1,840.40
26.04%
Expenses
2,708.20
1,740.10
55.63%
2,776.60
1,816.90
52.82%
2,296.80
1,686.00
36.23%
1,849.00
1,394.60
32.58%
EBITDA
714.40
399.40
78.87%
997.30
591.90
68.49%
644.30
488.20
31.97%
470.70
445.80
5.59%
EBIDTM
20.87%
18.67%
26.43%
24.57%
21.91%
22.45%
20.29%
24.22%
Other Income
93.50
77.90
20.03%
154.90
67.30
130.16%
78.60
48.30
62.73%
64.50
104.90
-38.51%
Interest
233.00
19.90
1,070.85%
248.80
10.50
2,269.52%
120.30
14.70
718.37%
30.00
22.50
33.33%
Depreciation
358.00
217.50
64.60%
363.70
212.20
71.39%
301.10
205.70
46.38%
230.80
201.50
14.54%
PBT
216.90
239.90
-9.59%
536.70
395.50
35.70%
30.10
316.10
-90.48%
257.40
256.60
0.31%
Tax
34.80
29.50
17.97%
82.10
58.60
40.10%
-4.80
49.30
-
147.30
46.30
218.14%
PAT
182.10
210.40
-13.45%
454.60
336.90
34.94%
34.90
266.80
-86.92%
110.10
210.30
-47.65%
PATM
5.32%
9.83%
12.05%
13.99%
1.19%
12.27%
4.75%
11.43%
EPS
0.84
1.20
-30.00%
2.61
1.99
31.16%
-0.35
1.56
-
0.39
1.15
-66.09%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
12,457.30
11,174.20
8,184.00
7,143.10
6,300.50
5,514.40
4,123.40
3,891.10
3,347.40
3,089.80
2,877.30
Net Sales Growth
45.48%
36.54%
14.57%
13.37%
14.26%
33.73%
5.97%
16.24%
8.34%
7.39%
 
Cost Of Goods Sold
4,169.90
3,663.10
2,718.40
2,243.70
1,989.50
1,896.60
1,636.10
1,446.60
1,290.40
1,255.60
1,186.10
Gross Profit
8,287.40
7,511.10
5,465.60
4,899.40
4,311.00
3,617.80
2,487.30
2,444.50
2,057.00
1,834.20
1,691.20
GP Margin
66.53%
67.22%
66.78%
68.59%
68.42%
65.61%
60.32%
62.82%
61.45%
59.36%
58.78%
Total Expenditure
9,630.60
9,054.70
6,691.40
5,841.00
5,043.50
4,390.60
3,294.30
2,911.60
2,584.30
2,394.00
2,190.20
Power & Fuel Cost
-
414.80
316.40
270.30
246.10
239.80
189.00
156.40
184.70
176.70
162.40
% Of Sales
-
3.71%
3.87%
3.78%
3.91%
4.35%
4.58%
4.02%
5.52%
5.72%
5.64%
Employee Cost
-
2,181.00
1,880.10
1,741.00
1,458.80
1,165.30
931.10
747.00
610.10
533.40
466.30
% Of Sales
-
19.52%
22.97%
24.37%
23.15%
21.13%
22.58%
19.20%
18.23%
17.26%
16.21%
Manufacturing Exp.
-
1,510.90
1,243.50
1,019.20
864.60
721.20
335.70
391.50
203.70
81.20
62.90
% Of Sales
-
13.52%
15.19%
14.27%
13.72%
13.08%
8.14%
10.06%
6.09%
2.63%
2.19%
General & Admin Exp.
-
765.90
181.50
270.50
182.10
53.00
56.80
21.70
144.60
165.70
131.80
% Of Sales
-
6.85%
2.22%
3.79%
2.89%
0.96%
1.38%
0.56%
4.32%
5.36%
4.58%
Selling & Distn. Exp.
-
221.60
243.80
235.90
266.30
277.50
98.20
107.40
100.80
108.70
118.90
% Of Sales
-
1.98%
2.98%
3.30%
4.23%
5.03%
2.38%
2.76%
3.01%
3.52%
4.13%
Miscellaneous Exp.
-
297.40
107.70
60.40
36.10
37.20
47.40
41.00
50.00
72.70
118.90
% Of Sales
-
2.66%
1.32%
0.85%
0.57%
0.67%
1.15%
1.05%
1.49%
2.35%
2.15%
EBITDA
2,826.70
2,119.50
1,492.60
1,302.10
1,257.00
1,123.80
829.10
979.50
763.10
695.80
687.10
EBITDA Margin
22.69%
18.97%
18.24%
18.23%
19.95%
20.38%
20.11%
25.17%
22.80%
22.52%
23.88%
Other Income
391.50
768.10
690.30
605.20
507.50
414.30
206.20
157.10
83.90
53.10
55.90
Interest
632.10
419.00
67.60
57.70
64.90
70.90
61.50
26.00
29.30
8.90
1.70
Depreciation
1,253.60
1,113.10
814.20
715.10
552.20
447.80
385.10
277.20
248.70
221.00
203.60
PBT
1,041.10
1,355.50
1,301.10
1,134.50
1,147.40
1,019.40
588.70
833.40
569.00
519.00
537.70
Tax
259.40
254.10
211.50
221.50
315.10
212.30
156.90
161.60
142.20
95.70
106.90
Tax Rate
24.92%
23.88%
17.77%
19.31%
25.94%
17.49%
26.65%
19.39%
19.49%
15.33%
19.88%
PAT
781.70
462.70
648.40
819.90
777.10
904.40
351.10
595.80
528.70
497.40
413.80
PAT before Minority Interest
576.90
643.00
771.60
925.60
899.80
1,001.70
431.80
671.80
587.40
528.40
430.80
Minority Interest
-204.80
-180.30
-123.20
-105.70
-122.70
-97.30
-80.70
-76.00
-58.70
-31.00
-17.00
PAT Margin
6.28%
4.14%
7.92%
11.48%
12.33%
16.40%
8.51%
15.31%
15.79%
16.10%
14.38%
PAT Growth
-23.69%
-28.64%
-20.92%
5.51%
-14.08%
157.59%
-41.07%
12.69%
6.29%
20.20%
 
EPS
6.51
3.85
5.40
6.83
6.47
7.53
2.92
4.96
4.40
4.14
3.45

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
17,866.90
8,432.50
7,626.90
6,705.80
6,098.00
5,180.80
4,837.70
4,033.80
3,270.60
3,026.70
Share Capital
600.30
600.30
600.00
600.00
300.00
300.00
100.00
100.00
100.00
100.00
Total Reserves
16,992.60
7,628.10
6,872.80
5,997.00
5,720.80
4,812.30
4,670.20
3,873.00
3,132.70
2,806.20
Non-Current Liabilities
20,742.30
6,802.70
5,496.90
2,684.70
2,122.30
2,006.50
2,304.60
2,421.30
1,377.90
1,262.00
Secured Loans
13,692.30
2,574.30
1,492.40
1,220.80
1,523.50
1,787.00
2,104.30
2,061.00
758.20
580.40
Unsecured Loans
1,598.20
1,424.20
1,469.20
1.40
2.10
2.80
3.90
11.40
11.40
25.80
Long Term Provisions
226.50
91.70
106.20
85.80
66.10
49.30
36.00
29.90
15.00
7.80
Current Liabilities
8,510.70
3,828.00
4,210.10
4,008.00
3,038.50
2,141.30
1,678.30
1,665.70
1,554.70
1,379.60
Trade Payables
3,983.10
1,608.50
1,513.90
1,325.10
1,198.30
1,005.30
739.70
609.80
429.30
347.20
Other Current Liabilities
1,673.80
1,031.20
1,840.20
1,784.40
1,374.70
870.10
698.20
527.10
706.20
612.30
Short Term Borrowings
2,480.20
896.00
594.20
667.60
261.20
130.30
97.20
394.90
261.00
243.50
Short Term Provisions
373.60
292.30
261.80
230.90
204.30
135.60
143.20
133.90
158.20
176.60
Total Liabilities
51,741.80
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
Net Block
29,467.70
6,569.00
6,363.90
5,971.10
4,471.00
3,699.50
3,625.10
1,748.30
1,629.90
1,525.20
Gross Block
35,321.40
11,233.00
10,220.90
9,147.40
7,095.00
5,873.80
5,436.10
3,403.60
3,034.20
2,701.70
Accumulated Depreciation
5,853.70
4,664.00
3,857.00
3,176.30
2,624.00
2,174.30
1,811.00
1,655.30
1,404.30
1,176.50
Non Current Assets
39,407.80
11,718.40
10,614.20
8,750.80
6,979.20
5,647.70
5,149.00
4,415.70
3,812.80
3,111.80
Capital Work in Progress
7,317.00
4,110.40
2,800.20
2,196.00
1,898.90
1,302.80
839.20
2,239.50
1,676.40
1,205.60
Non Current Investment
742.30
370.20
743.20
108.50
182.50
63.80
188.80
26.80
0.00
64.50
Long Term Loans & Adv.
683.20
483.80
436.40
402.00
335.80
437.20
319.70
350.10
336.90
252.00
Other Non Current Assets
1,197.60
185.00
270.50
73.20
91.00
144.40
176.20
51.00
169.60
64.50
Current Assets
12,334.00
8,382.30
7,600.40
5,325.00
4,888.50
4,148.60
4,047.70
3,970.90
2,562.60
2,638.80
Current Investments
1,326.50
1,217.70
1,208.70
857.60
829.30
611.40
1,065.00
874.70
230.30
700.40
Inventories
4,243.70
2,298.20
1,866.60
1,435.90
1,031.60
722.50
635.30
542.40
452.70
376.60
Sundry Debtors
3,573.20
2,058.20
1,503.30
1,223.70
1,291.80
1,063.90
883.20
714.50
770.50
599.80
Cash & Bank
2,400.10
1,747.50
2,015.40
998.60
1,057.20
1,322.80
1,044.30
1,538.60
937.50
804.40
Other Current Assets
790.50
660.20
713.10
543.60
678.60
428.00
419.90
300.70
171.60
157.60
Short Term Loans & Adv.
456.40
400.50
293.30
265.60
153.10
54.70
24.10
134.70
75.80
81.80
Net Current Assets
3,823.30
4,554.30
3,390.30
1,317.00
1,850.00
2,007.30
2,369.40
2,305.20
1,007.90
1,259.20
Total Assets
51,741.80
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
1,852.50
1,176.60
1,159.70
1,283.10
1,154.60
662.10
640.00
370.60
210.70
560.70
PBT
897.10
983.10
1,067.70
870.90
1,002.60
610.00
849.70
751.30
624.10
537.70
Adjustment
1,685.00
1,245.00
709.60
921.40
472.60
355.70
204.40
42.00
74.00
134.00
Changes in Working Capital
-501.00
-789.50
-423.80
-165.10
-29.10
-106.50
-211.10
-176.20
-354.00
37.70
Cash after chg. in Working capital
2,081.10
1,438.60
1,353.50
1,627.20
1,446.10
859.20
843.00
617.10
344.10
709.40
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-228.60
-262.00
-193.80
-344.10
-291.50
-197.10
-203.00
-246.50
-133.40
-148.70
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-14,281.80
-1,699.10
-3,624.70
-1,558.90
-713.80
-684.00
-498.50
-1,141.70
-508.70
-938.10
Net Fixed Assets
-260.40
-284.70
-130.90
744.40
-280.60
-177.90
-215.90
-216.90
-57.90
-322.80
Net Investments
-3,990.70
202.20
-456.90
-890.30
107.80
-310.70
-79.30
-3,688.10
328.50
125.80
Others
-10,030.70
-1,616.60
-3,036.90
-1,413.00
-541.00
-195.40
-203.30
2,763.30
-779.30
-741.10
Cash from Financing Activity
13,048.70
242.10
2,564.00
387.60
-241.70
-239.70
-177.50
1,067.60
186.20
426.00
Net Cash Inflow / Outflow
619.40
-280.40
99.00
111.80
199.10
-261.60
-36.00
296.50
-111.80
48.60
Opening Cash & Equivalents
653.70
897.00
824.70
659.30
449.00
710.20
757.50
457.50
557.00
474.00
Closing Cash & Equivalent
1,294.80
653.70
897.00
824.70
659.30
449.00
710.20
757.50
462.60
557.00

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
146.53
68.53
62.27
54.97
50.17
42.59
39.74
33.10
26.93
24.21
ROA
1.79%
4.03%
5.73%
6.94%
9.25%
4.55%
7.64%
7.96%
8.72%
8.47%
ROE
4.98%
9.83%
13.16%
14.26%
18.00%
8.74%
15.37%
16.31%
17.22%
15.68%
ROCE
5.37%
8.30%
11.30%
14.35%
16.11%
8.92%
12.59%
13.93%
15.30%
15.75%
Fixed Asset Turnover
0.48
0.77
0.74
0.78
0.85
0.73
0.89
1.05
1.09
1.12
Receivable days
91.14
79.19
69.67
72.86
77.96
86.05
74.35
80.16
80.09
69.48
Inventory Days
105.87
92.60
84.38
71.47
58.05
60.00
54.81
53.71
48.47
48.54
Payable days
278.58
209.62
230.92
81.60
81.98
87.98
78.68
71.28
58.15
55.73
Cash Conversion Cycle
-81.57
-37.84
-76.87
62.74
54.04
58.07
50.48
62.59
70.42
62.29
Total Debt/Equity
1.01
0.60
0.58
0.40
0.40
0.44
0.48
0.62
0.35
0.30
Interest Cover
3.14
15.54
20.88
19.72
18.12
10.57
33.05
25.90
71.12
317.29

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014

News Update:


  • Biocon’s arm gets European Commission’s nod for YESAFILI
    20th Sep 2023, 17:11 PM

    The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway

    Read More
  • Biocon’s arm completes integration of Viatris’ biosimilars business in North America
    6th Sep 2023, 17:31 PM

    As a result of the completion of this integration, Biocon Biologics is expected to grow its employee population to over 150 employees in North America

    Read More
  • Biocon’s arm acquires manufacturing facility of Eywa Pharma
    2nd Sep 2023, 14:37 PM

    The facility is acquired for a total consideration of $7.7 million

    Read More
  • CCI approves Kotak Special Situations Fund's proposed investment in Biocon’s arm
    14th Aug 2023, 16:38 PM

    The investment will help Biocon Biologics' acquisition of the biosimilars business of its partner Viatris

    Read More
  • Biocon reports 11% fall in Q1 consolidated net profit
    11th Aug 2023, 11:52 AM

    Total consolidated income of the company increased by 58.57% at Rs 3516.10 crore for Q1FY24

    Read More
  • Biocon - Quarterly Results
    10th Aug 2023, 19:54 PM

    Read More
  • USFDA completes two cGMP inspections at Malaysia Facility of Biocon Biologics’ arm
    22nd Jul 2023, 12:59 PM

    These inspections were conducted between July 10, 2023 and July 20, 2023

    Read More
  • Biocon’s arm expands footprint in emerging markets
    5th Jul 2023, 18:00 PM

    The company’s subsidiary has completed the integration of the acquired biosimilars business in over 70 countries

    Read More
  • Biocon’s arm launches HULIO injection in United States
    4th Jul 2023, 09:47 AM

    Biocon Biologics, which recently announced its acquisition of Viatris’ global biosimilars business, has secured multiple biosimilar approvals in the U.S., Europe, and over 100 countries across the globe

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.